Abivax Provides Operational And Key Program Update, Phase 3 ABTECT Trial Evaluating Obefazimod In Moderately To Severely Active Ulcerative Colitis On Track To Complete Enrollment In Early Q1 2025; Cash Position Allows For Runway Into Q4 2025 Through ABTECT 8-Week Induction Top-Line Results
Portfolio Pulse from Benzinga Newsdesk
Abivax SA (NASDAQ: ABVX) provided an update on its Phase 3 ABTECT trial for obefazimod in ulcerative colitis, which is on track to complete enrollment in early Q1 2025. The company expects top-line results in early Q2 2025 and has sufficient cash to fund operations through Q4 2025. Leadership changes include Sylvie Grégoire as Chair of the Board, Dr. Fabio Cataldi as Chief Medical Officer, and Dr. David Zhang as Chief Strategy Officer.
July 15, 2024 | 8:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Abivax SA (NASDAQ: ABVX) announced that its Phase 3 ABTECT trial for obefazimod in ulcerative colitis is on track to complete enrollment in early Q1 2025, with top-line results expected in early Q2 2025. The company has sufficient cash to fund operations through Q4 2025. Leadership changes include Sylvie Grégoire as Chair of the Board, Dr. Fabio Cataldi as Chief Medical Officer, and Dr. David Zhang as Chief Strategy Officer.
The update on the Phase 3 ABTECT trial and the company's cash position extending to Q4 2025 are positive indicators for investors, suggesting continued progress and financial stability. Leadership changes may also bring new strategic directions.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100